From: Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir
 | Relative change in bilirubin | 95% Confidence Interval | P-value |
---|---|---|---|
Main model – with HCV seropositivity |  |  |  |
Baseline ALP (/5Â IU increase) | 0.99 | 0.98, 1.00 | 0.04 |
TDF use at baseline | 0.86 | 0.72, 1.00 | 0.10 |
HCV seropositivity | 0.80 | 0.66, 0.97 | 0.02 |
Baseline bilirubin | 0.98 | 0.96, 1.00 | 0.05 |
Sensitivity analysis 1 – with methadone use |  |  |  |
ALP at baseline (/5Â IU increase) | 0.99 | 0.98, 1.00 | 0.01 |
TDF use at baseline | 0.83 | 0.70, 0.99 | 0.04 |
Methadone use | 0.77 | 0.65, 0.92 | 0.01 |
Baseline bilirubin | 0.98 | 0.96, 1.00 | 0.04 |
Sensitivity analysis 2 – with IVDU |  |  |  |
ALP at baseline (/5Â IU increase) | 0.99 | 0.98, 1.00 | 0.02 |
TDF use at baseline | 0.83 | 0.70, 1.00 | 0.05 |
IVDU | 0.85 | 0.70, 1.00 | 0.08 |
Baseline bilirubin | 0.98 | 0.96, 1.00 | 0.02 |